Specifically, they recently demonstrated that only in pancreatic cancer PDXs with mutant TP53, which is characterized by a higher glucose uptake compared to wild-type TP53 tumors, FX11 was able to inhibit the pyruvate-to-lactate conversion. This evidence concerns the gene TP53 and familial pancreatic carcinoma.